Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared ...
Novartis will support the career development programme of the European & Developing Countries Clinical Trials Partnership (EDCTP). The programme aims to provide early- to mid-career researchers in sub-Saharan Africa with an opportunity to train and develop their clinical research skills....
Novartis a annoncé aujourd’hui une nouvelle stratégie visant à élargir l’accès des patients et la disponibilité de sa gamme de médicaments en Afrique subsaharienne, qui regroupe la plus vaste population au monde de patients mal desservis. Novartis souhaite également être le partenaire de choix de...
Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in the world. Novartis also aspires to be the partner of choice for governments and NGOs to stre...
Today, the Government of Ghana announced the availability of hydroxyurea for the treatment of people with sickle cell disease (SCD), marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD. The launch foll...
Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3
Today, on World Sickle Cell Day, Novartis is helping raise awareness on the disease and its complications by sharing a collection ...
The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West an...
For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).
The report is divided into four chapters based on our corporate responsibility (CR) material clusters and the global health and CR strategic prioritie...
For the fifth consecutive year, Novartis is publishing an annual Corporate Responsibility (CR) Report. The report is divided into four chapters based on our CR material clusters: access to healthcare, innovation, patient health and safety and ethical business practices. Each chapter provides re...
Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry.
This is the fourth consecutive year N...